Make it stand out.
Whatever it is, the way you tell your story online can make all the difference.
Active Dermatomyositis
A phase 3 double-blind, randomised, placebo-controlled, multicentre study investigated the effect of intravenous immunoglobulin (IVIg) in 95 patients with active dermatomyositis and found that 57.7% of patients receiving IVIg experienced treatment-emergent adverse events (TEAEs) compared to 22.9% on placebo (1). Eight thromboembolic events occurred in six patients on IVIg. The study concluded that IVIg has a favourable safety profile for treating adult dermatomyositis patients.
Reference
Aggarwal R, Schessl J, Charles-Schoeman C, Bata-Csörgő Z, Dimachkie MM, Griger Z, Moiseev S, Oddis CV, Schiopu E, Vencovský J, Beckmann I, Clodi E, Levine T; ProDERM investigators. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024 Jan 17;26(1):27. doi: 10.1186/s13075-023-03232-2. PMID: 38233885; PMCID: PMC10792872.
Active Dermatomyositis
A phase III parallel assignment study investigated the effect of botulinum toxin type A (Masport) and DYSPORT for the treatment of glabellar lines in 262 subjects and found that Masport is equally safe and effective as DYSPORT with a 50 unit dose up to 120 days (1).
Reference
Hedayat K, Ehsani AH. A Phase III Clinical Study of the Efficacy and Safety of Botulinum Toxin Type A (MASPORT) with DYSPORT for the Treatment of Glabellar Lines. Aesthetic Plast Surg. 2024 Jan 17. doi: 10.1007/s00266-023-03766-5. Epub ahead of print. PMID: 38233684.